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Despite continuous advances in the 
knowledge of the biology of acute myeloid 
leukemia (AML), the prognosis of AML 
patients treated with standard chemo-
therapy is still poor, especially in the 
elderly (> 60 y). It should be considered 
that AML mainly develops in the elderly, 
with a median age at diagnosis of 68 y 
and a growing incidence over 65 y. AML 
accounts for about 25% of all adult leu-
kemias in the western world, and it is the 
second most frequent form of leukemia 
following chronic lymphocytic leukemia.1 
Given the extremely poor prognosis of 
AML, there is a need for novel targeted 
and less toxic therapies, especially for 
patients who are over 60 y or those who 
develop resistance to traditional chemo-
therapeutic drugs. Constitutively active 
phosphatidylinositol 3-kinase (PI3K)/
Akt/mammalian target of rapamycin 
(mTOR) signaling is a common feature of 
AML patients, where it negatively influ-
ences response to therapeutic treatments.2 
A major issue in the efforts to treat AML 
patients is the inability of current thera-
pies to efficiently target and eradicate 
leukemia initiating cells (LICs), which 
are the cells thought to initiate and main-
tain the leukemic phenotype.3 In a recent, 
open-label phase II trial performed by the 
Italian GIMEMA cooperative group, the 
efficacy and safety of the drug combina-
tion consisting of low-dosage clofarabine 
with the allosteric mTOR complex 1 
(mTORC1) inhibitor temsirolimus (CCI-
779, Torisel©) was studied in a group of 
elderly patients with refractory/relapsed 
AML.4 Some encouraging clinical results 
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were seen. Clofarabine is a second-gener-
ation purine nucleoside analog that has 
been synthesized to overcome the limita-
tions and incorporate the best properties 
of fludarabine and cladribine.5 Although 
clofarabine is quite widely used for the 
treatment of AML patients, surprisingly 
there were no data in the literature regard-
ing the effects of this drug on signaling 
pathways of AML cells.
We recently performed a transla-
tional study, related to the above reported 
clinical trial, in which we assessed the 
therapeutic potential of a combination 
consisting of clofarabine with temsiro-
limus (CLO-TOR)6 in AML cells. The 
drug combination displayed synergistic 
cytotoxic effects against a panel of AML 
cell lines and primary cells from AML 
patients. Treatment with CLO-TOR 
induced a G
0
/G
1
-phase cell cycle arrest, 
apoptosis and autophagy. Cell cycle arrest 
was characterized by an induction of 
p27Kip1, which was much stronger when 
the two drugs were used in combination 
than as monotherapy. We also observed 
that the CLO-TOR combination was 
more effective than either drug alone in 
dephosphorylating key components of the 
PI3K/Akt/mTOR pathway, including the 
translational repressor, 4E-BP1, which 
mainly regulates oncogenic protein syn-
thesis (Fig. 1). 4E-BP1 phosphorylation is 
usually quite resistant to treatment with 
rapamycin/rapalogs in AML cells, and 
this could at least partly explain why this 
class of drugs only display a limited effi-
cacy in AML.2 Indeed, we observed that 
eIF4F complex formation was markedly 
downregulated by CLO-TOR treatment 
in AML patient samples, and this sug-
gested that the drug combination effi-
ciently targeted translation of oncogenic 
proteins. The CLO-TOR combination 
also affected STAT3 and c-Myc expres-
sion in AML cell lines. c-Myc downregu-
lation could be critical for the cytotoxic 
effects of CLO-TOR, as a decrease in 
c-Myc levels could result in the inhibition 
of ribosome synthesis that, in turn, causes 
proliferative arrest and/or apoptosis. Last 
but not least, CLO-TOR was pro-apop-
totic in an AML patient blast subpopula-
tion (CD34+/CD38−/CD123+), which is 
enriched in putative LICs. Importantly, 
the combined treatment was more effec-
tive than either drug alone in inducing 
apoptosis in this leukemic cell subset. 
CLO-TOR was able to downregulate the 
phosphorylation levels of S6RP at Ser 
235/236 and of Akt at Ser 473, imply-
ing targeting of both mTORC1 and 
mTORC2 in the CD34+/CD38−/CD123+ 
subset (Fig. 1). How could clofarabine 
increase the previously reported cytotoxic 
activity of an mTORC1 inhibitor toward 
LICs? Indeed, the majority of LICs are 
quiescent and therefore not sensitive to 
various chemotherapeutic agents that kill 
rapidly dividing cells.2 However, it should 
be recalled that clofarabine, besides 
inhibiting ribonucleotide reductase and 
DNA polymerase, directly targets the 
mitochondria and induces apoptosis, even 
in quiescent cells5 (Fig. 1). Over the last 
few years, the results of two other clinical 
trials in which chemotherapy was com-
bined with mTORC1 blockers have been 
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be used in vivo in humans. Indeed, our 
study has unequivocally documented the 
existence of a synergism between clofara-
bine and temsirolimus at clinically rele-
vant concentrations.6 However, our study 
has also highlighted additional and unex-
pected effects of clofarabine on AML cell 
signaling pathways that could certainly 
help in designing more effective therapeu-
tic protocols, in which clofarabine will be 
combined with mTORC1 modulators or 
other signal transduction inhibitors, for 
treatment of AML patients.
disclosed.7,8 Although the treatments 
appeared to be feasible and quite well tol-
erated by the patients, the clinical results 
were not satisfactory. In the first study, 
the synergy between the chemotherapy 
regimen and sirolimus was not confirmed. 
Thus, future investigations were planned 
with different schedules to clarify the 
clinical and biochemical effects of siro-
limus in AML cells.7 For this reason, we 
believe that pre-clinical studies are of the 
utmost importance for a better assessment 
of the efficacy of combined treatments to 
Figure 1. a cartoon highlighting the effects of clofarabine and temsirolimus on aML cells. arrows indicate activating events, whereas perpendicular 
lines indicate inhibitory events.
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